July 2012

SureSilencing shRNA Plasmid Handbook

For genomewide, plasmid-based RNA interference



Sample & Assay Technologies

QIAGEN Sample and Assay Technologies

QIAGEN is the leading provider of innovative sample and assay technologies, enabling the isolation and detection of contents of any biological sample. Our advanced, high-quality products and services ensure success from sample to result.

QIAGEN sets standards in:

- Purification of DNA, RNA, and proteins
- Nucleic acid and protein assays
- microRNA research and RNAi
- Automation of sample and assay technologies

Our mission is to enable you to achieve outstanding success and breakthroughs. For more information, visit www.qiagen.com.

Product Use Limitations

SureSilencing shRNA Plasmids are intended for molecular biology applications. This product is not intended for the diagnosis, prevention, or treatment of a disease.

Contents

Kit Contents and Vector Information

SureSilencing shRNA Plasmid Kit Catalog no.	Varies
SureSilencing shRNA vector	4
Negative Control shRNA* vector	1
Handbook	1

* The negative control shRNA is a scrambled artificial sequence which does not match any human, mouse, or rat gene.

Note: These plasmids are **transformation-grade only** and are prepared and meant for introduction and amplification in bacteria **first**. These plasmids **are not** transfection-grade and **are not** provided in a large amount or of high enough quality for direct introduction into a mammalian cell line of interest.

Storage

All components included with this catalog number are shipped with cold ice packs. The plasmids must be stored at -20 °C and are guaranteed for 6 months from the date received.

Intended Use

SureSilencing shRNA Plasmids are intended for molecular biology applications. These products are not intended for the diagnosis, prevention, or treatment of a disease.

Safety Information

When working with chemicals, always wear a suitable lab coat, disposable gloves, and protective goggles. For more information, please consult the appropriate material safety data sheets (MSDSs). These are available online in convenient and compact PDF format at www.qiagen.com/Support/MSDS.aspx where you can find, view, and print the MSDS for each QIAGEN kit and kit component.

24-hour emergency information

Emergency medical information in English, French, and German can be obtained 24 hours a day from:

Poison Information Center Mainz, Germany

Tel: +49-6131-19240

Quality Control

In accordance with QIAGEN's ISO-certified Quality Management System, each lot of SureSilencing shRNA Plasmid Kit is tested against predetermined specifications to ensure consistent product quality.

Product Specifications

Vector information

Plasmids contain either one of three markers identifiable by the catalog number scheme:

- Plasmids with catalog numbers ending in the letter "H" contain the hygromycin resistance gene for selection of stably transfected cells.
- Plasmids with catalog numbers ending in the letter "N" contain the neomycin resistance gene for selection of stably transfected cells.
- Plasmids with catalog numbers ending in the letter "P" contain the puromycin resistance gene for selection of stably transfected cells.
- Plasmids with catalog numbers ending in the letter "G" contain a gene encoding a Green Fluorescent Protein (GFP) for fluorescence microscopy-based tracking or FACS-based enrichment of transiently transfected cells.

The shRNA sequences and the negative control sequence are provided with each product information sheet included with the plasmid set. The sequences were cloned downstream of the U1 promoter of the plasmid. For detailed information about the parent vectors including vector maps and sequences, see Appendixes A, B, C, and D.

Equipment and Reagents to Be Supplied by User

When working with chemicals, always wear a suitable lab coat, disposable gloves, and protective goggles. For more information, consult the appropriate material safety data sheets (MSDSs), available from the product supplier.

For transformation and plasmid purification

- Competent *E. coli* cells: in general, any strain designed for the amplification of plasmid may be used. We recommend JM109 competent cells (Promega® cat. no. L1001 or 2001).
- Ampicillin, molecular biology grade (from any source)
- LB medium and agar (Gibco®)
- Plasmid purification kit, such as:
    - EndoFree® Plasmid Maxi Kit (QIAGEN cat. no. 12362) for purification of up to 500 µg transfection-grade plasmid DNA, **or**
    - QIAfilter Plasmid Midi Kit (QIAGEN cat. no. 12243) for fast purification of up to 100 µg transfection-grade plasmid DNA, **plus** EndoFree Plasmid Buffer Set (QIAGEN cat. no. 19048), an endotoxin-free buffer set for 10 mega- or 5 giga- transfection-grade DNA preps

Recipe for LB-ampicillin agar plates:

Add 15 g agar to 1 L LB medium. Autoclave. Allow the medium to cool to 50 °C before adding ampicillin (50 µg/ml, final concentration). Pour 30–35 ml of medium into 85 mm Petri dishes. Let the agar solidify. Store at 4 °C for up to 1 month or at room temperature (15–25°C) for up to 1 week.

Notes:

- Because plasmid DNA purity and quality are crucial for optimal transfection efficiencies and therefore the success of the shRNA-based gene suppression, we do not recommend using mini-preparations of plasmid DNA for transfection.
- For guidance on carrying out transformations and plasmid preps, and performing quality control testing on plasmid preps prior to transfection, refer to Appendix E.

For transfection

- We recommend using Attractene Transfection Reagent (QIAGEN cat. no. 301004)
- Antibiotic (molecular biology- and/or tissue culture-grade): hygromycin, G418 (for use with neomycin-resistant plasmids), or puromycin

For real-time RT-PCR verification of gene suppression

- RT^2 First Strand Kit (QIAGEN cat. no. 330401)
- RT^2 SYBR® Green qPCR Mastermix (choose the correct one for the instrumentation in your laboratory)

RT^2 SYBR Green ROX qPCR Mastermix:

For all ABI and Stratagene® instrumentation

Eppendorf® Mastercycler® ep *realplex* instruments with ROX filter

Catalog no.	Size
330520	For 2 RT^2 Profiler PCR Arrays or 200 x 25 µl reactions
330522	For 12 RT^2 Profiler PCR Arrays
330523	For 24 RT^2 Profiler PCR Arrays

RT^2 SYBR Green Fluor qPCR Mastermix:

For Bio-Rad® iCycler®, MyiQ™, and iQ™5 instrumentation

Catalog no.	Size
330510	For 2 RT^2 Profiler PCR Arrays
330512	For 12 RT^2 Profiler PCR Arrays
330513	For 24 RT^2 Profiler PCR Arrays

RT² SYBR Green qPCR Mastermix:

For instrumentation that does not require a reference dye:

BioRad (MJ Research) Opticon, Opticon 2, and Chromo 4™

Roche LightCycler® 480 System

Eppendorf Mastercycler ep *realplex* instruments without ROX filter set

Catalog no.	Size
330500	For 2 RT² Profiler PCR Arrays or 200 x 25 µl reactions
330502	For 12 RT² Profiler PCR Arrays
330503	For 24 RT² Profiler PCR Arrays

- RT² qPCR Primer Assay targeting the suppressed target gene of interest and a housekeeping gene, such as ACTB of GAPD, to normalize the real-time PCR results

Introduction

RNA interference, a now commonplace and popular method for exploring gene function, suppresses the expression of a specific gene of interest in transformed mammalian cell culture. Upon suppression, missing or altered activities in the cell can be attributed to the function of the affected gene. The most commonly used technique, small interfering RNA (siRNA), proves useful for some applications, but not all. This technique works optimally with cells known to be easily and readily transfected with nucleic acid, but not in cells with low transfection efficiencies. Small interfering RNA does not allow transfected cells to be identified, preventing both enrichment and determination of transfection efficiency. Additionally, due to a lack of selection markers, siRNA only works under transient and not stable transfection conditions, preventing the exploration of long-term gene-suppression effects.

Principle and procedure

SureSilencing shRNA plasmids are designed using an experimentally verified algorithm. These constructs specifically knock down the expression of specific genes by RNA interference and allow for enrichment or selection of transfected cells. Each vector expresses a short hairpin RNA, or shRNA, under control of the U1 promoter and either the hygromycin, neomycin, or puromycin resistance gene, or the GFP gene. Hygromycin, neomycin or puromycin resistance permits selection of stably transfected cells. GFP helps estimate transfection efficiencies, tracks transfected cells by fluorescence microscopy, and permits FACS-based enrichment of transiently transfected cells. The ability to select or track and enrich shRNA-expressing cells brings RNA interference to cell lines with lower transfection efficiencies. Unlike siRNA, plasmid-based shRNA also provide a renewable source of RNA interference reagent.

Our experimentally verified shRNA design algorithm assures gene-specificity and efficacy. An advanced specificity search in addition to BLAST built into the algorithm helps to reduce potential off-target effects. At least two of the provided SureSilencing shRNA Plasmids are guaranteed to knock down expression of the targeted gene at the RNA level by at least 70 percent in transfected cells upon selection for antibiotic resistance or FACS-based enrichment for GFP expression.

Benefits of SureSilencing shRNA Plasmids:

- Enrich or select: Plasmids are available with either GFP marker, hygromycin, neomycin, or puromycin resistance, enabling either

enrichment and short-term studies or selection and the study of the long-term effects of gene suppression.

- Success guaranteed*: Knock down expression of any targeted human, mouse, or rat gene by at least 70 percent. Control for non-specific and off-target effects.
- Convenient and cost-effective: Use standard transfection methods. Plasmids provide a renewable source of RNA interference.

* At least two of the four provided pre-designed SureSilencing shRNA Plasmids are guaranteed to knock down expression of the targeted gene at the RNA level by at least 70 percent as measured by real-time qRT-PCR in transfected cells upon FACS-based enrichment for GFP expression or selection for neomycin or puromycin resistance as described in this Handbook.



Figure 1. Overview of SureSilencing shRNA Plasmid procedure.

Protocol, Section A: Transfection

Note: Plasmid DNA purify and quality are crucial for optimal transfection efficiencies, and therefore the success of shRNA-based gene suppression. For guidance on carrying out transformations and plasmid preps, and performing quality control testing on plasmid preps prior to transfection, please refer to Appendix E.

We recommend the use of Attractene Transfection Reagent (QIAGEN cat. no. 301004). For virtually all cell lines tested, Attractene Transfection Reagent is an exceptional transfection reagent, providing maximal transfection efficiency and minimal toxicity.

If you have already optimized a transfection reagent and protocol for your cell line of interest, you may use that protocol to transfect the SureSilencing shRNA Plasmids into the same cell line. Just be sure that the original protocol optimization used **plasmids** and determined **% transfected cells** rather than relying on relative reporter activities.

We recommend using reverse transfection protocols with Attractene Transfection Reagent. This is due to the time savings and improved reproducibility using this method compared to traditional forward transfection methods. Attractene Transfection Reagent will also work well as a reagent for traditional forward transfection methods.

The following protocols are written on a **per well** basis, and are designed for the transfection of an adherent cell line, 293H (Invitrogen®), with Attractene Transfection Reagent, using a 24-well cell culture plate. **We recommend that you set up three (3) replicate transfections for each of the four gene-specific and the negative control SureSilencing shRNA Plasmids using an optimized transfection protocol.**

Reverse Transfection Procedure

Note: This procedure is a general guideline; optimal conditions and amounts should be determined for each new cell line or cell type that is being transfected. This procedure is sometimes termed "forward transfection."

Procedure

1. **Dispense 59.6 µl of Opti-MEM® I Reduced-Serum Medium (Gibco) into the appropriate well of a 24-well cell culture plate.**

2. **Dispense 0.40 µg (1 µg/µl) of the appropriate gene-specific shRNA plasmid or the negative control shRNA plasmid into the Opti-MEM.** Mix by gently rocking the plate back and forth several times.
3. **Add 3 µl of Attractene Transfection Reagent (that is 7.5 µl of Attractene per µg of plasmid).**

   Mix by gently rocking the plate back and forth several times.
4. **Incubate the plate for 10-15 min at room temperature (15–25ºC) to allow transfection complex formation.**
5. **During the above incubation, prepare the cells.**
   1. Wash the cells to be used with Dulbecco's PBS without calcium and magnesium, trypsinize, and harvest the cells by centrifugation.
   2. Wash once with cell culture media by resuspension and re-centrifugation.
   3. Resuspend the cells in fresh growth medium containing 10% fetal bovine serum and 1% NEAA, to a density of 0.8–3.2 X 10^5 cells per ml.
6. **After the 15 min incubation for transfection complex formation is completed (Step 4), mix the tube containing the cells by inversion or gentle pipeting, and aliquot 500 µl of the prepared cell suspension into the well containing the Attractene-plasmid complexes.** Mix gently by rocking the plate back and forth.
7. **Incubate the cells at 37 °C in a CO_2 incubator for 24 to 48 hours.**
8. **Determine the transfection efficiency as the number of transfected cells divided by the total number of cells, and begin the enrichment or selection process described in Section B.**

Traditional Transfection Procedure

Note: This procedure is intended as a general guideline; optimal conditions and amounts should be determined for each new cell line or cell type transfected.

1. **One day after transfection, seed 2–8 X 10^4 cells in each well of a 24-well plate (for approximately 30–35 percent confluence) with 500 µl of growth medium.**
2. **On the day of transfection, add 0.40 µg (1 µg/µl) of each gene-specific shRNA plasmid and the negative control shRNA plasmid into separate 59.6 µl aliquots of Opti-MEM I Reduced-Serum Medium (Gibco). Mix gently.** Prepare separate mixtures for each replicate well of cells to be transfected with the same plasmid.

3. **For each well, add 3.0 µl Attractene Transfection Reagent into 60 µl Opti-MEM–DNA mix (7.5 µl Attractene Transfection Reagent per µg plasmid. Mix gently, and incubate all mixtures for 10–15 min at room temperature to allow complex formation.**
4. **While complex formation is taking place, gently aspirate the medium from the cells and add 500 µl fresh medium to the cells.**
5. **Add the mixture of shRNA and Attractene Transfection Reagent in medium to the appropriate well containing cells and normal growth medium.** Mix gently.
6. **Incubate the cells at 37 °C in a CO_2 incubator for 24 to 48 hours.**
7. **Determine the transfection efficiency as the number of transfected cells divided by the total number of cells, and begin the selection or enrichment process described in Section B.**

Note: Our rigorous real-time RT-PCR protocol for verifying suppression by RNA interference relies on triplicate transfections for each gene-specific shRNA design and the negative control shRNA for statistically significant results. See Appendix F of this Handbook for more details.

Section B: Selection or Enrichment

Unless your transfection efficiency is routinely greater than 90%, we strongly recommend enriching the transfected cell population. If you chose plasmids containing the hygromycin resistance gene, select for transfected cells using hygromycin. If you chose plasmids containing the neomycin resistance gene, select for transfected cells using neomycin (G418). If you chose plasmids containing the puromycin resistance gene, select for transfected cells using puromycin. If you chose GFP-containing plasmids, enrich the transfected cells by Fluorescence Activated Cell Sorting (FACS®).

Selection for Antibiotic Resistance

Different cell lines normally have different levels of antibiotic resistance. Before transfection, the minimum antibiotic concentration necessary to kill untransfected cells must be determined by generating a dose response curve. The minimum concentration needed to kill untransfected cells is known as the "effective concentration". The effective concentration will depend on the cell line, growth rate, and state of confluence during growth. In general, more confluent cells tolerate higher concentrations of antibiotic; therefore, maintain the cells in a sub-confluent state during selection.

To generate a dose-response curve for either hygromycin or neomycin (G418) selection:

Plate untransfected cells at a low density (≤ 10% confluence) in normal growth medium containing the following antibiotic concentrations in separate wells:

0, 100, 200, 400, 600, 800, and 1000 μg ml^{-1}

To generate a dose-response curve for puromycin selection:

Plate untransfected cells at a low density (≤10% confluence) in normal growth medium containing different puromycin concentrations in separate wells:

0, 1, 2, 4, 6, 8, and 10 μg ml^{-1}

Procedure to generate a dose-response curve:

1. **Allow the cells to grow until the "0" concentration point reaches confluence.**
2. **Replace the media every 2 days during the selection process.**
3. **Count the number of cells in each well and plot the cell number versus the antibiotic concentration.**
4. **The minimum concentration of antibiotic that kills all of the cells is the effective concentration used for selection.**

Procedure to select transfected cells for antibiotic resistance:

1. **After transfection, re-plate cells at a low density (≤10% confluence).**
2. **Grow cells in medium containing the effective concentration of antibiotic.**
3. **Prepare control plates for all selection experiments to ensure that selection conditions are still working as previously observed:**
   1. Plate untransfected cells at the same density in medium containing the effective concentration of antibiotic. No growth should be observed from these plates.
   2. Plate transfected cells at the same density in medium without antibiotic. Uninhibited growth should be observed from these plates.
4. **Replace the medium every 2–3 days with fresh medium. Re-plate cells every week.** Continue the selection for up to 2 weeks or until enough cells are available for generating a frozen stock and for isolating total RNA.
5. **As soon as possible, be sure to freeze a stock of the stably transfected cells.** Be sure to generate stable transfections for each gene-specific shRNA plasmid and the negative control shRNA plasmid.

6. **Once a stably transfected population of cells is available, continue to grow these cells in media containing a reduced or "maintenance" concentration of antibiotic, typically 25–50% effective concentration.**

Special Note for Stable Transfection Applications

Achieving a high level of knockdown in the initial population of stably transfected cells can be difficult. The plasmid integrates into the cell line genome randomly, and the initial "polyclonal" population represents several such integration sites. Each integration site affects the relative level of expression of the shRNA construct differently and therefore the effectiveness of the knockdown. Some sites provide more expression of shRNA and better knockdown of the GOI than others. The level of knockdown in the "polyclonal" population represents the weighted average knockdown of all of the integration sites.

To obtain an even greater and more consistent level of knockdown, this "polyclonal" population of stably transfected cells can be cloned by limiting dilution to generate separate populations of stably transfected cells. Each new "clone" (or "monoclonal" population) will represent a single integration site, its level of shRNA expression, and its level of GOI knockdown. Screen for the clone or clones that provides the greatest level of knockdown using a real-time qRT-PCR procedure similar to the one described above in Appendix F.

Sample procedure:

1. **Separately suspend a stock culture of the "polyclonal" populations of cells stably transfected with the 2 shRNA designs with the greatest apparent level of knockdown.** Determine their concentrations. Choose one of the replicate transfections at random.
2. **Serially dilute each suspended stock down to a concentration of approximately 1 cell per 400 µl.**
3. **Plate 200 µl of each dilution per well in separate 96-well cell culture plates so that approximately every other well will receive one cell.**
4. **Allow the cells to grow to large colonies in medium containing the maintenance concentration of the same antibiotic drug used for the first stage of selection (hygromycin, G418, or puromycin).**
5. **Re-plate each well population separately into a larger well.** Allow them to grow to a larger number, and re-plate again into an even larger well. Continue this process iteratively until enough cells are available for generating a frozen stock and for isolating total RNA.

6. **Repeat the real-time qRT-PCR-based verification of shRNA knockdown on selected clones from each plate.**
7. **Use one or more clones that demonstrate the greatest percent knockdown from each of the 2 best designs in your subsequent gene function assays and studies.**

Enrichment for GFP

1. **Consult with your FACS instrument manufacturer or your local FACS core facility for details on enriching GFP-expressing cells using this method.** Peak excitation of the GFP from the SureSilencing plasmids occurs at 505 nm, with a shoulder at 480 nm, and peak emission occurs at 515 nm. Please note that these peak excitation and peak emission wavelengths differ from those of other sources of GFP**.**
2. **Save the sort parameters as well as an image of the flow cytometer or FACS analysis trace for troubleshooting purposes.**
3. **Be sure to enrich all cell populations, including those transfected with each gene-specific shRNA plasmid and those transfected with the negative control shRNA.**

Note: Target gene suppression may also be analyzed at the individual cell level, for example by immunofluorescence or morphology scoring. The expression of the GFP from the SureSilencing™ plasmids can be monitored by fluorescence microscopy using an excitation filter of 470 ± 20nm (470 / 40 nm) and an emission filter of 515 nm (long pass)

Section C: Assay Effects of Silencing Gene Expression

There are many ways to characterize the effects on cells brought on by a decrease in the expression of a gene meditated by RNA interference. The following is a brief list of possibilities. Your experiments need not be limited to these suggestions, however.

Cells may be harvested, and RNA isolated for gene expression analysis using:

- QIAGEN RT^2 Profiler PCR Arrays
- QIAGEN RT^2 qPCR Primer Assays and RT^2 SYBR Green Mastermixes

  (As described in Appendix F, verifying the suppression of gene expression)

Cells may be harvested, and protein isolated for:

- SDS-PAGE and Western blot verification
- QIAGEN Multi-Analyte ELISArray Kits
- QIAGEN Single Analyte ELISArray Kits
- Biochemical assays

Cells may be left in wells or plates for:

- Cell biological assays such as morphology and immunofluorescence (GFP only)
- Steady-state labeling or uptake assays (neomycin or puromycin recommended)

SureSilencing shRNA Plasmid Kit FAQ

What is the SureSilencing shRNA Plasmids guarantee?

We guarantee that at least 2 of the set of 4 SureSilencing shRNA Plasmids will knock down the expression of the target gene by at least 70% in transfected cells by real-time qRT-PCR in target shRNA-transfected cells relative to negative control shRNA-transfected cells upon FACS-based enrichment for GFP expression or selection for antibiotic resistance (best clone). For the antibiotic selection, you need to select individual clones and test to find the highest knockdown. The initial "polyclonal" population will not work optimally and is not guaranteed for knockdown efficiency. Please follow the recommendations in this handbook in order to insure the optimal level of knockdown from these plasmids and the best method for detecting knockdown. If you can demonstrate each plasmid's failure to knock down gene expression as described, please contact a Technical Support representative to discuss your results and be prepared to provide the results as an Excel® file in an email attachment. If a product failure is verified, we will send you another set of plasmids with 4 pre-designed shRNA constructs for free.

Should I use the SureSilencing shRNA Plasmids with the GFP or antibiotic resistance marker?

Use the SureSilencing shRNA Plasmids with the antibiotic resistance marker for stable transfection to achieve long-term knockdown (a cell line permanently knocking down the gene of interest) and to perform gene function assays involving the cell for a long period of time (anything greater than a day). Having multiple antibiotic resistance genes from which to choose enables you to introduce one or more SureSilencing shRNA into cells that are already resistant to an alternative antibiotic. Use the SureSilencing shRNA Plasmids with GFP for transient transfections and gene function assays that can be performed with the cells quickly (in less than a day), but only if you have access and the resources to use a flow cytometry core facility.

What transfection method should I use with the SureSilencing shRNA Plasmids?

We recommend using Attractene Transfection Reagent (QIAGEN cat. no. 301004). For the majority of cell lines tested, it is an exceptional reagent, providing a superior combination of maximal transfection efficiency with minimal cytotoxicity. If you have previously optimized a transfection method for plasmids into your cell line that results in high transfection efficiencies, you may use that method to transfect the SureSilencing shRNA Plasmids. In order to optimize transfection conditions, use a plasmid system that encodes an easily

screened reporter, such as GFP or beta-galactosidase. If your cells do not transfect well with lipid-based or chemical transfection methods, electroporation via methods such as those provided by Lonza/Amaxa may be a useful alternative.

Can I use the SureSilencing shRNA Plasmids with primary cells or macrophages or for injection into live animals?
No, we do not recommend using the SureSilencing shRNA Plasmids with primary cells or macrophages or other cell lines that tend to be difficult to transfect with expression plasmids by traditional methods. For these applications, we instead recommend finding a viral-based delivery system. Similarly, we do not recommend using the SureSilencing shRNA Plasmids for RNA interference in live animals. The SureSilencing shRNA Plasmids are meant for *in vitro* use only. The delivery of any method of RNA interference into live animals to specific target tissues or organs is a difficult procedure for which no manufacturer has a viable solution.

Can the SureSilencing shRNA Plasmids be use for viral-based delivery?
The SureSilencing shRNA plasmids cannot be directly used for viral delivery, nor do they have convenient restriction sites to re-clone the U1-based shRNA expression cassette into another vector or viral expression system. In fact, the U1 transcription termination sequence necessary for proper expression of the shRNA can disrupt the process of viral production. Inserts for shRNA are more easily synthesized as oligonucleotides and then cloned into an appropriate expression system. So instead, we recommend screening the set of four shRNA sequences in another model system amenable to lipid-mediated transfection to find the best sequence. Then, use the shRNA insert sequence information provided with the purchase of our plasmids to have the necessary oligonucleotides synthesized for cloning into your viral-based delivery system of choice.

Do the SureSilencing shRNA Plasmids contain inducible promoters?
No, SureSilencing shRNA Plasmids with inducible promoters are not available. These promoters are meant to control the timing of silencing particularly for stable shRNA transfections for essential genes or for differentiation model systems. However, they tend to be too leaky for RNA interference. That is, they still express a certain amount of the shRNA of interest even under repressed conditions. We do not recommend a specific vector system for this application. However, you are welcome to screen our shRNA sequences in another cell model system, and then use the shRNA insert sequence information provided with the purchase of our plasmids to have the necessary oligonucleotides synthesize for cloning into your inducible expression system of choice.

Troubleshooting Guide

This troubleshooting guide may be helpful in solving any problems that may arise. For more information, see also the Frequently Asked Questions page at our Technical Support Center: www.qiagen.com/FAQ/FAQList.aspx. The scientists in QIAGEN Technical Services are always happy to answer any questions you may have about either the information and protocols in this handbook or sample and assay technologies (for contact information, see back cover or visit www.qiagen.com).

	Comments and suggestions
Poor plasmid transformation efficiency into *E. coli*	
	Consult the manufacturer's instructions for the competent *E. coli* cells.
Poor yield of plasmid from transformed *E. coli*	
	Consult the manufacturer's instructions for the plasmid DNA purification kit.
Low transfection efficiency	
a) Experimental conditions not optimized	Transfection efficiencies primarily depend upon the cell line used. Therefore, it is very important to optimize the transfection conditions for each cell type under study. Variables to consider, when optimizing the transfection conditions include cell density, cell viability, amount of DNA, ratio of DNA to transfection reagent, transfection complex formation time, and transfection incubation time (see the detailed protocols for our recommendations). Do not use siRNA to optimize transfection efficiency.

	Comments and suggestions
b) Quantification of transfected cells is suboptimal.	a) If using the GFP-containing SureSilencing shRNA Plasmid: Stain the cells with a nuclear DNA stain to count both transfected (GFP-positive) cells and the total number of cells (nuclear DNA stain) in the same fluorescent view of the same microscope field. Be sure to obtain numbers from several different randomly-chosen microscope fields in the interior (not toward the edges) of the cell culture well. **Do not** try to use the phase (cell) and fluorescence (GFP) views separately to estimate or count the number of total and number of transfected cells, respectively. b) If using the SureSilencing shRNA Plasmid set carrying an antibiotic resistance marker: Use another plasmid instead, with a reporter gene that allows you to **count** transfected cells. **Do not** use one that relies on the total activity of reporter assay (e.g., CAT) in the entire cell population. For example, if using beta-galactosidase, fix and stain the cells with X-gal to visualize and count the total number of cells and the number of transfected (blue-stained) cells rather than assaying activity in total cell lysate.
Interpreting knockdown results from low transfection efficiencies	
a) Perform an extra step to obtain a more pure population of transfected cells.	Select for antibiotic resistance, or enrich by FACS for GFP expression.
b) Calculate knockdown using transfection efficiency (for GFP-containing shRNA Plasmids only).	The approximate apparent level of suppression in transfected cells is equal to the observed percent knockdown divided by the experimentally determined transfection efficiency. For example, eighty (80) percent transfection efficiency and seventy (70) percent observed knockdown (30 percent of control) means an approximate percent suppression in transfected cells of 87.5 (70/0.8).

	Comments and suggestions
No stably transfected cell population obtained after selection	
a) Low transfection efficiency	a) Determine the observed transfection efficiency and optimize again, if necessary. b) If you have not done so already, repeat the plasmid purification using an endotoxin-free plasmid purification kit, particularly if excessive mammalian cell toxicity is observed upon transfection. c) Attempt to linearize the plasmid before transfection as described in this Handbook to help facilitate integration into your cell line's genome.
b) Antibiotic concentration too high	Only use the minimum antibiotic concentration necessary to kill untransfected cells as defined by your dose response curve.
c) Cells plated at too low a density during selection	Plating cells at extremely low densities may inhibit growth due to the effective dilution of autocrine growth factors. Conditioned medium may be used to promote growth, or repeat the transfection and then the selection at a higher cell density.
d) Suppressed gene is an essential gene for viability	The shRNA successfully suppressed the expression of the target gene, but the target gene is required for the survival of the cells. In other words, the very act of suppressing the gene of interest itself killed the stably transfected cells. To explore the function of essential genes, you may need to develop and optimize an inducible promoter system for shRNA in your laboratory or seek other alternatives.

	Comments and suggestions
Selection completed but low level of knockdown or stable transfection	
a) Cells plated at too high a density during selection	The use of too many cells during the selection reduces the effective concentration of neomycin. Repeat the transfection and then repeat the selection at a lower cell density. Preserve all of the transfected cells by dividing the entire population across a greater number of plates. Conditioned medium may be used to promote growth at these lower densities.
b) Antibiotic concentration too low	Be sure to use at least the minimum antibiotic concentration necessary to kill untransfected cells as defined by your dose response curve.
c) Isolation of individual clones from pooled population is required to achieve maximal knockdown	Choose the two pooled populations which exhibit the greatest level of knockdown. Sub-clone to select for single integration events. Briefly, dilute the cells such that a concentration of 0.5 cells per well of a 384 well dish is achieved. Select 10 colonies from each of the pooled population to assay for knockdown.
Knockdown not distinguishable by real-time PCR	
a) Poor transfection efficiency and/or no selection or enrichment	Make sure that your transfection efficiency is optimized and that you have selected or enriched the cell population for transfected cells. You must be looking at a population of cells that is nearly 100 percent transfected for an accurate determination of knockdown.
b) Poor real-time PCR reproducibility	Make sure that your triplicate real-time PCR determinations of threshold cycle values demonstrate a high degree of reproducibility with a standard deviation of roughly 0.25 to 0.33 cycles. A seventy (70) percent knockdown of expression will be observed as only a 1.74 difference in normalized C_t values for the gene of interest between pure populations of negative control and gene-specific shRNA transfected cells. This specific level of reproducibility is required to reliably detect such a difference.

	Comments and suggestions
c) Low level of expression of gene of interest	To accurately determine knockdown by real-time PCR, the level of expression of the gene of interest in control or untransfected cells should be at least reasonably expressed with a C_T value less than 30. Real-time PCR cannot determine the relative expression of genes expressed at a lower level (C_T >30) with enough reproducibility to detect a seventy (70) percent knockdown of expression. Try using more input RNA (up to 5 µg) in the reverse transcription reaction and only dilute the completed reaction by four-fold, adding 60 instead of 100 µl of ddH_2O, but still use 10 µl of the dilution to setup PCR.
d) Real-time PCR analysis not performed properly	Make sure that real-time PCR analysis was set up and performed properly. Consult the Troubleshooting Guide of the RT^2 qPCR Primer Assay Handbook if using the RT^2 qPCR Primer Assays and RT^2 SYBR Green qPCR Mastermixes from QIAGEN. If using other reagents for real-time PCR, consult the original manufacturers' recommendations and suggestions.

Real-time PCR decrease in expression at RNA level observed but no effect seen at the level of protein or biochemical assay

Timing of the experiment may preclude observable protein or biochemical changes	The RT-PCR verification will confirm that expression has been decreased at the level of messenger RNA and that the SureSilencing shRNA Plasmids functioned correctly. A change in the RNA level for a particular gene product does not necessarily immediately correlate with a change in the amount of protein in the cell. If the protein has a long half-life, then changes in protein level will take much longer to occur than changes in the RNA level. The protein level changes may therefore not be observed in a GFP-based transient transfection experiment, but should be detected in a longer term stable transfection based on hygromycin, neomycin, or puromycin selection.

Note 1: Only use real-time PCR to determine the extent of knockdown. Other RNA detection methods (e.g. Northern blot analysis or conventional PCR) may not be quantitative enough to observe a 70% knockdown. Western blot analysis is also unreliable because the success of knockdown at the protein level also depends on the quality of the antibody and the biological half-life of the protein, whereas RNA interference specifically acts at the RNA level.

Note 2: Most mammalian expression plasmids, like the SureSilencing shRNA Plasmids, do not replicate in mammalian cells. They are eventually lost due to dilution caused by cell growth and division causing random distribution to daughter cells. The use of a selectable marker (such as antibiotic resistance) on the same or another plasmid (at one-tenth the amount) selects for the very rare incorporation of the plasmid DNA into cell line genome by an unknown mechanism. Once integrated, the plasmid sequence is replicated with the rest of the genome and passed to both daughter cells. Selection for the expression of GFP in such a fashion is not possible, meaning that GFP may only be used for transient transfection experiments.

References

QIAGEN maintains a large, up-to-date online database of scientific publications utilizing QIAGEN products. Comprehensive search options allow you to find the articles you need, either by a simple keyword search or by specifying the application, research area, title, etc.

For a complete list of references, visit the QIAGEN Reference Database online at www.qiagen.com/RefDB/search.asp or contact QIAGEN Technical Services or your local distributor.

Appendix A: Neomycin Parent Vector Sequence

pGeneClip™ Neomycin Vector

This vector can be obtained from Promega Corporation, Madison, WI. Call one of the following numbers for ordering or technical information:

US: 1-800-356-9526

Outside US: 608-274-4330



pGeneClip™ Neomycin Vector sequence reference points:

Base pairs	4758
T7 RNA polymerase transcription initiation site	1
U1 promoter (human, -392 to +1)	46-438
10bp spacer	439-448
U1 termination sequence	449-465
SP6 RNA polymerase promoter (-17 to +3)	527-546
SP6 RNA polymerase promoter primer binding site	529-547
Binding region of pUC/M13 reverse sequencing primer	564-585
SV40 early enhancer/promoter	798-1216
SV40 minimum origin of replication	1114-1179
Coding region of neomycin phosphotransferase	1251-2045
Synthetic poly(A) signal	2080-2128
Beta-lactamase (Ampr) coding region	3080-3940
Binding region of pUC/M13 forward sequencing primer	4692-4715
T7 RNA polymerase promoter (-17 to +3)	4742-3

Insert Sequence

The sense strand of the insert for each provided plasmid will read as follows:

1. "G" — only if the shRNA specific sequence does not already start with a "G"
2. The shRNA sequence listed on the individual product information sheet
3. "CTTCCTGTCA" — the loop of the short hairpin RNA structure
4. The complementary sequence to the above shRNA sequence
5. "CT" — to engineer a new diagnostic *Pst* I site indicating the presence of insert

This sequence is inserted between positions 438 and 439 in the plasmid sequence below directly in the middle of the bold, underlined sequence of TCTC^GCAG. The complete plasmid sequence can be accessed at: http://www.SABiosciences.com/RNAiResource.php

Appendix B: GFP Parent Vector Sequence

pGeneClip™ hMGFP Vector

This vector can be obtained from Promega Corporation, Madison, WI. Call one of the following numbers for ordering or technical information:

US: 1-800-356-9526

Outside US: 608-274-4330



pGeneClip™ hMGFP Vector sequence reference points:

Base pairs	5267
T7 RNA polymerase transcription initiation site	1
U1 promoter (human, -392 to +1)	46-438
10bp spacer	439-448
U1 termination sequence	449-465
SP6 RNA polymerase promoter (-17 to +3)	527-546
SP6 RNA polymerase promoter primer binding site	529-547
Binding region of pUC/M13 reverse sequencing primer	564-585
CMV enhancer/promoter	801-1550
Chimeric intron	1690-1822
hMGFP open reading frame	1880-2563
Synthetic poly(A) signal	2589-2637
Beta-lactamase (Ampr) coding region	3589-4449
Binding region of pUC/M13 forward sequencing primer	5201-5224
T7 RNA polymerase promoter (-17 to +3)	5250-3

Insert Sequence:

The sense strand of the insert for each provided plasmid will read as follows:

1. "G" — only if the shRNA specific sequence does not already start with a "G"
2. The shRNA sequence listed on the individual product information sheet
3. "CTTCCTGTCA" — the loop of the short hairpin RNA structure
4. The complementary sequence to the above shRNA sequence
5. "CT" — to engineer a new diagnostic *Pst* I site indicating the presence of insert

This sequence is inserted between positions 438 and 439 in the plasmid sequence below directly in the middle of the bold, underlined sequence of TCTC^GCAG. The complete plasmid sequence can be accessed at: http://www.SABiosciences.com/RNAiResource.php

Appendix C: Puromycin Parent Vector Sequence

pGeneClip™ Puromycin Vector

This vector can be obtained from Promega Corporation, Madison, WI. Call one of the following numbers for ordering or technical information:

US: 1-800-356-9526

Outside US: 608-274-4330



pGeneClip™ Puromycin Vector sequence reference points:

Base pairs	4561
T7 RNA polymerase transcription initiation site	1
U1 promoter (human, -392 to +1)	46-438
10bp spacer	439-448
U1 termination sequence	449-465
SP6 RNA polymerase promoter (-17 to +3)	527-546
SP6 RNA polymerase promoter primer binding site	529-547
Binding region of pUC/M13 reverse sequencing primer	564-585
SV40 early enhancer/promoter	798-1216
SV40 minimum origin of replication	1114-1179
Puromycine-N-acetyltransferase coding region	1239-1838
Synthetic poly(A) signal	1883-1931
Beta-lactamase (Ampr) coding region	2883-3743
Binding region of pUC/M13 forward sequencing primer	4495-4518
T7 RNA polymerase promoter (-17 to +3)	4545-3

Insert Sequence:

The sense strand of the insert for each provided plasmid will read as follows:

1. "*G*" — only if the shRNA specific sequence does not already start with a "*G*"
2. The shRNA sequence listed on the individual product information sheet
3. "CTTCCTGTCA" — the loop of the short hairpin RNA structure
4. The complementary sequence to the above shRNA sequence
5. "CT" — to engineer a new diagnostic *Pst* I site indicating the presence of insert

This sequence is inserted between positions 438 and 439 in the plasmid sequence below directly in the middle of the bold, underlined sequence of TCTC ^ GCAG. The complete plasmid sequence can be accessed at: http://www.SABiosciences.com/RNAiResource.php

Appendix D: Hygromycin Parent Vector Sequence

pGeneClip™ Hygromycin Vector

This vector can be obtained from Promega Corporation, Madison, WI. Call one of the following numbers for ordering or technical information:

US: 1-800-356-9526

Outside US: 608-274-4330



pGeneClip™ Hygromycin Vector sequence reference points:

Base pairs	4989
T7 RNA polymerase transcription initiation site	1
U1 promoter (human, -392 to +1)	46-438
10bp spacer	439-448
U1 termination sequence	449-465
SP6 RNA polymerase promoter (-17 to +3)	527-546
SP6 RNA polymerase promoter primer binding site	529-547
Binding region of pUC/M13 reverse sequencing primer	564-585
SV40 early enhancer/promoter	798-1216
SV40 minimum origin of replication	1114-1179
Hygromycin phosphotransferase coding region	1251-2276
Synthetic poly(A) signal	2311-2359
Beta-lactamase (Ampr) coding region	3311-4171

Insert Sequence:

The sense strand of the insert for each provided plasmid will read as follows:

1. "G" — only if the shRNA specific sequence does not already start with a "G"

2. The shRNA sequence listed on the individual product information sheet

3. "CTTCCTGTCA" — the loop of the short hairpin RNA structure

4. The complementary sequence to the above shRNA sequence

5. "CT" — to engineer a new diagnostic *Pst* I site indicating the presence of insert

This sequence is inserted between positions 438 and 439 in the plasmid sequence below directly in the middle of the bold, underlined sequence of TCTC^GCAG. The complete plasmid sequence can be accessed at: http://www.SABiosciences.com/RNAiResource.php

Appendix E: Plasmid Preparation and Quality Control

E. coli Transformation

1. **Use 2 µl of each stock plasmid solution to separately transform competent *E. coli* cells following the manufacturer's protocol.** Store the remaining stock plasmid at –20 °C.

Note: In order to amplify a known amount of plasmid, the *E. coli* cells do not need to be extremely competent.

2. **Plate each transformation onto separate LB agar plates containing ampicillin.** Grow overnight at 37 °C.

Plasmid Purification

1. Pick one colony for each plate with a sterile loop or toothpick and inoculate separate 2.5 ml cultures of LB medium containing 50 µg/ml ampicillin. Incubate with shaking at 37 °C until just a hint of turbidity is observed in the culture (3 to 6 h).
2. **Use the small cultures to inoculate 250 ml cultures of LB medium containing 50 µg/ml ampicillin.** Incubate with shaking at 37 °C, overnight.
3. **Isolate the cells and purify plasmid DNA according to the Plasmid Purification Kit manufacturer's instructions for high copy number plasmids.**

   Note: Save the remaining stocks of the plasmids provided for future transformations and amplifications. However, use these remaining stocks only if your amplified plasmid preparation is compromised. When the amplified stocks become depleted, use your amplified preparation as the working stock solution, both for transfections and for new transformations and amplifications.

4. **Optional plasmid quality control and diagnostic restriction digest.**

To verify that you have purified plasmids containing shRNA insert, you may perform a *Pst* I restriction enzyme digestion of a small aliquot of each plasmid preparation. All three plasmid types, with either neomycin resistance or puromycin resistance or GFP, will generate a diagnostic pair of bands on an agarose gel upon *Pst* I digestion:

Parent vector	***Pst* I fragments**
SureSilencing Neomycin Vector	3827 bp and 991 bp
SureSilencing Puromycin Vector	3209 bp and 1402 bp
SureSilencing Hygromycin Vector	3892 bp and 1147 bp
SureSilencing GFP Vector	4130 bp and 1197 bp

To insure optimal (especially transient) transfection efficiency, also characterize a small aliquot of each undigested plasmid on the same agarose gel. The DNA should be predominantly supercoiled and not extensively nicked.

Note: To avoid nicking the plasmid, make sure the NaOH/SDS lysis (Solution II) step of the plasmid preparation protocol does not proceed for any longer than the time specified.



Figure 1. Example of plasmid preparation quality control. Two SureSilencing shRNA Plasmids with GFP and their *Pst* I digests are characterized side-by-side on an agarose gel along with a 1-kb ladder. The *Pst* I digests contain the two diagnostic bands indicating the presence of shRNA insert. The uncut plasmid preparations predominantly contain the faster migrating supercoiled form and very small amounts of slower migrating nicked plasmid or plasmid concatamers.

5. Optional linearization of plasmid for stable transfections.

To increase the likelihood of integration and shorten the time needed to isolate stable transfectants, you may wish to "linearize" the plasmid containing the neomycin or puromycin resistance markers prior to transfection as described below:

1. Perform a restriction enzyme digest on enough of your plasmid preparation for the necessary transfections with either *Sca* I, *Bsa* I, or *Dra* III for the neomycin plasmids or with either *Sca* I, *Ecl*HK I, *Nae* I, or *NgoM* IV for the puromycin plasmids, in order of preference.
2. Re-purify the DNA according to a standard phenol extraction procedure.
3. Use the purified "linearized" plasmid DNA material to setup the stable transfection.

Appendix F: Real-time RT-PCR Protocol for Verifying Suppression

A detailed description of the theory behind RNA interference validation using real-time PCR may be found in the white paper entitled, "Did your RNAi experiment work? Reliably validating RNA interference with real-time PCR." The white paper may be downloaded here:
http://www.SABiosciences.com/manuals/shRNAwhitepaper.pdf

For statistically significant results, the method relies on triplicate transfections for each gene-specific shRNA design and the negative control shRNA. It also requires triplicate real-time PCR reactions to characterize the targeted gene of interest (GOI) and a housekeeping gene (HKG) to normalize the results using the total RNA sample from each transfection. Typical housekeeping genes include β-actin and GAPDH.

The triplicate reactions for each gene in all five triplicate transfections may be conveniently set up in a 96-well PCR plate as depicted in Table 1. The table represents a 96-well plate. The reactions in the first set of six numbered columns will characterize expression of the GOI in the indicated RNA samples, while the second set of six numbered columns will characterize expression of the HKG in the corresponding RNA samples.

Table 1. Setting up real-time PCR verification of suppression.

	1	2	3	4	5	6	7	8	9	10	11	12
A	Design1 Txn1 P1 P2 P3			NC Design Txn3 P1 P2 P3			Design1 Txn1 P1 P2 P3			NC Design Txn3 P1 P2 P3		
B	Design1 Txn2 P1 P2 P3			Design3 Txn1 P1 P2 P3			Design1 Txn2 P1 P2 P3			Design3 Txn1 P1 P2 P3		
C	Design1 Txn3 P1 P2 P3			Design3 Txn2 P1 P2 P3			Design1 Txn3 P1 P2 P3			Design3 Txn2 P1 P2 P3		
D	Design2 Txn1 P1 P2 P3			Design3 Txn3 P1 P2 P3			Design2 Txn1 P1 P2 P3			Design3 Txn3 P1 P2 P3		
E	Design2 Txn2 P1 P2 P3			Design4 Txn1 P1 P2 P3			Design2 Txn2 P1 P2 P3			Design4 Txn1 P1 P2 P3		
F	Design2 Txn3 P1 P2 P3			Design4 Txn2 P1 P2 P3			Design2 Txn3 P1 P2 P3			Design4 Txn2 P1 P2 P3		
G	NC Design Txn1 P1 P2 P3			Design4 Txn3 P1 P2 P3			NC Design Txn1 P1 P2 P3			Design4 Txn3 P1 P2 P3		
H	NC Design Txn2 P1 P2 P3			BLANK			NC Design Txn2 P1 P2 P3			BLANK		
	Samples in column 1 to 6 are amplified using PCR primers specific for the GOI.						**Samples in column 7 to 12 are amplified using PCR primers specific for the HKG.**					

Unless otherwise indicated, follow the protocols described in the *RT² qPCR Primer Assay Handbook* included with RT² qPCR Primer Assays.

1. Isolate RNA.

1. Isolate total RNA from each of the 15 transfections.
2. For cultured cells, use the Qiagen RNeasy® Mini Kit (Catalog # 74104). Be sure to include the recommended DNase treatment step.
3. Also, make sure to perform the RNA quality control described in the *RT² qPCR Primer Assay Handbook*.

2. Reverse transcribe RNA (first strand cDNA template synthesis).

1. Perform one reverse transfection for each of the 15 total RNA samples (one per transfection).
2. Follow the instructions in the *RT² qPCR Primer Assay Handbook* included with the RT² qPCR Primer Assays.
3. For convenient pipetting below, dilute each completed 20-µl RT reaction 10-fold by adding 180 µl ddH_2O.

3. Prepare primer set and master mix cocktail.

For real-time PCR, prepare two separate cocktails, one for the GOI and one for the HKG, using the following recipe:

Component	Volume
2x RT^2 SYBR Green Mastermix	600 µl
ddH_2O	72 µl
RT^2 primer set for GOI OR HKG	48 µl
Final Volume	**720 µl**

4. **Set up the reactions.**
   Add 15 µl of the appropriate primer set and master mix cocktail and 10 µl of the appropriate diluted cDNA template (RT reaction) to the appropriate PCR wells as outlined in Figure 3.

5. **Perform real-time PCR.**
   Perform PCR as described in the *RT^2 qPCR Primer Assay Handbook* included with the RT^2 qPCR Primer Assays.

6. **Analyze data.** An Excel-based data analysis template that automatically performs the calculations below is available for download from our website at the following address:
   http://www.SABiosciences.com/rnaidataanalysis.php

   1. Separately determine the average of the technical triplicate PCR C_T values and their standard deviations for both genes in each of the replicate transfections of each design and the negative control.

   2. Separately calculate individual ΔC_T values for each biological replicate transfection of each design and the negative control:

GOI-specific shRNA ΔC_T =
AVG GOI-specific shRNA C_T (GOI) – AVG GOI-Specific shRNA C_T (HKG)

GOI-specific shRNA ΔC_T STDEV = $\sqrt{STDEV_{GOI}^2 + STDEV_{HKG}^2}$

Negative Control shRNA ΔC_T =
AVG Negative Control shRNA C_t (GOI) – AVG Negative Control shRNA C_T (HKG)

Negative Control shRNA ΔC_T STDEV = $\sqrt{STDEV_{GOI}^2 + STDEV_{HKG}^2}$

3. Calculate the average ΔC_T and its standard deviation across the biological replicates for each design.

4. Calculate the average $\Delta\Delta C_T$ and its standard deviation for each design:

$\Delta\Delta C_T$ = Gene-specific shRNA ΔC_T – Negative Control shRNA ΔC_T

$\Delta\Delta C_T$ STDEV = $\sqrt{STDEV^2_{Gene-Specific\ \Delta Ct} + STDEV^2_{NegativeControl\ \Delta Ct}}$

5. Calculate the average knockdown and its 95% confidence interval:

Percent Knockdown = 100 – (100 x 2 ^ (-$\Delta\Delta C_T$))
Lower 95 % Confidence Interval Boundary = 100 – (100 × 2 ^ (- $\Delta\Delta C_T$ + $\Delta\Delta$ C_T STDEV))
Upper 95 % Confidence Interval Boundary = 100 – (100 × 2 ^ (- $\Delta\Delta C_T$ - $\Delta\Delta$ C_T STDEV))

6. Interpretation

Successful design: Observed KD $\geq$ 70% and an upper 95% C.I. boundary $\geq$55.5 %

Failed design: Observed KD < 33.3% and a lower 95% C.I. boundary <55.5 %

Two out of the four designs should be successful. Use at least two of the four pre-designed plasmids that demonstrate the greatest percent knockdown in your subsequent gene function assays and studies.

Ordering Information

Product	Contents	Cat. no.
SureSilencing shRNA Plasmid, GFP	Gene-specific shRNA cloned into a plasmid containing a GFP marker; five plasmids are provided for each gene, including 4 gene-specific shRNA plasmids and one negative control plasmid	Varies
SureSilencing shRNA Plasmid, Hygromycin	Gene-specific shRNA cloned into a plasmid containing a hygromycin marker; five plasmids are provided for each gene, including 4 gene-specific shRNA plasmids and one negative control plasmid	Varies
SureSilencing shRNA Plasmid, Neomycin	Gene-specific shRNA cloned into a plasmid containing a neomycin marker; five plasmids are provided for each gene, including 4 gene-specific shRNA plasmids and one negative control plasmid	Varies
SureSilencing shRNA Plasmid, Puromycin	Gene-specific shRNA cloned into a plasmid containing a puromycin marker; five plasmids are provided for each gene, including 4 gene-specific shRNA plasmids and one negative control plasmid	Varies

For up-to-date licensing information and product-specific disclaimers, see the respective QIAGEN kit handbook or user manual. QIAGEN kit handbooks and user manuals are available at www.qiagen.com or can be requested from QIAGEN Technical Services or your local distributor.

Limited License Agreement for SureSilencing shRNA Plasmids

Use of this product signifies the agreement of any purchaser or user of the product to the following terms:

1. The product may be used solely in accordance with the protocols provided with the product and this handbook and for use with components contained in the kit only. QIAGEN grants no license under any of its intellectual property to use or incorporate the enclosed components of this kit with any components not included within this kit except as described in the protocols provided with the product, this handbook, and additional protocols available at www.qiagen.com. Some of these additional protocols have been provided by QIAGEN users for QIAGEN users. These protocols have not been thoroughly tested or optimized by QIAGEN. QIAGEN neither guarantees them nor warrants that they do not infringe the rights of third-parties.
2. Other than expressly stated licenses, QIAGEN makes no warranty that this kit and/or its use(s) do not infringe the rights of third-parties.
3. This kit and its components are licensed for one-time use and may not be reused, refurbished, or resold.
4. QIAGEN specifically disclaims any other licenses, expressed or implied other than those expressly stated.
5. The purchaser and user of the kit agree not to take or permit anyone else to take any steps that could lead to or facilitate any acts prohibited above. QIAGEN may enforce the prohibitions of this Limited License Agreement in any Court, and shall recover all its investigative and Court costs, including attorney fees, in any action to enforce this Limited License Agreement or any of its intellectual property rights relating to the kit and/or its components.

For updated license terms, see www.qiagen.com.

www.qiagen.com

Australia ■ techservice-au@qiagen.com

Austria ■ techservice-at@qiagen.com

Belgium ■ techservice-bnl@qiagen.com

Brazil ■ suportetecnico.brasil@qiagen.com

Canada ■ techservice-ca@qiagen.com

China ■ techservice-cn@qiagen.com

Denmark ■ techservice-nordic@qiagen.com

Finland ■ techservice-nordic@qiagen.com

France ■ techservice-fr@qiagen.com

Germany ■ techservice-de@qiagen.com

Hong Kong ■ techservice-hk@qiagen.com

India ■ techservice-india@qiagen.com

Ireland ■ techservice-uk@qiagen.com

Italy ■ techservice-it@qiagen.com

Japan ■ techservice-jp@qiagen.com

Korea (South) ■ techservice-kr@qiagen.com

Luxembourg ■ techservice-bnl@qiagen.com

Mexico ■ techservice-mx@qiagen.com

The Netherlands ■ techservice-bnl@qiagen.com

Norway ■ techservice-nordic@qiagen.com

Singapore ■ techservice-sg@qiagen.com

Sweden ■ techservice-nordic@qiagen.com

Switzerland ■ techservice-ch@qiagen.com

UK ■ techservice-uk@qiagen.com

USA ■ techservice-us@qiagen.com

QIAGEN

1073538 07/2012

Sample & Assay Technologies